Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
View Patent ↗The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
1. A pharmaceutical composition comprising a compound that is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt and one or more pharmaceutically acceptable excipients; wherein the composition is suitable for providing sustained release of the compound.
2. The composition of claim 1 , wherein the composition is a unit dosage form.
3. The composition of claim 2 , wherein the unit dosage form is a tablet.
4. The composition of claim 2 , wherein the unit dosage form is a capsule.
5. The composition of claim 1 , wherein the unit dosage form further comprises an enteric layer.
6. The composition of claim 2 , wherein the unit dosage form comprises from about 5 to about 1000 mg of the compound.
7. The composition of claim 1 , wherein said one or more excipients comprise lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, or methyl cellulose.
8. The composition of claim 1 , wherein said one or more excipients comprise microcrystalline cellulose.
9. The composition of claim 8 , wherein said one or more excipients comprise lactose.
10. The composition of claim 9 , wherein the unit dosage form is a tablet.
11. The composition of claim 1 , wherein said one or more excipients comprise lactose.
12. The composition of claim 1 , wherein (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt is a crystalline salt.
13. The composition of claim 12 , wherein said crystalline salt is a 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid salt.
14. The composition of claim 13 , wherein the unit dosage form is a tablet.
15. The composition of claim 1 , wherein the composition suitable for providing sustained release of the compound is administered orally.
16. The composition of claim 1 , wherein the composition suitable for providing sustained release of the compound is administered topically.